|
- 2019
Still a hopeless case for personalized oncology? Pancreatic cancer revisitedKeywords: pancreatic cancer, personalized oncology, ge-nomics, RNA subtypes, prognosis Abstract: In many cancer entities, morphomolecularly informed, individually tailored, targeted treatment has strongly improved patient outcome. Recent advances in immune oncology in concert with novel targeted molecular agents even brought pharmacological “cure” within reach for a considerable number of patients with metastatic solid tumors. However, as always in the last decades, one of the large tumor entities is left behind: pancreatic cancer
|